Citrobacter freundii
Antibiotic |
% Susceptible 2010 |
% Susceptible 2012 |
% Susceptible 2014 |
% Susceptible 2016 |
% Susceptible 2018 |
Ampicillin | 7 |
0 | 0 | 0 | 0 |
Azithromycin | |||||
Aztreonam | 85 |
89 | 94 |
88 | 86 |
Cefazolin | 0 |
0 | 0
0 |
0 |
|
Cefepime | + |
+ | +
+ |
+ |
|
Ceftazidime | 82 |
86 | 91 |
87 | 81 |
Ceftriaxone | 84 |
86 | 88 |
81 | 78 |
Cefuroxime | 15 |
0 | 0
0 |
0 |
|
Ciprofloxacin | 93 |
91 | 95 |
97 | 92 |
Clarithromycin | |||||
Clindamycin | - |
- | - |
- | - |
Doxycycline | 80 |
80 | + |
+ | + |
Erythromycin | - |
- | - |
- | - |
Gentamicin | 95 |
93 | 97 |
98 | 94 |
Imipenem | 100 |
100 | 97 |
97 | 91 |
Levofloxacin | 96 | 93 | 95 | 99 | 94 |
Meropenem | + | 100 | 100 | 100 | 100 |
Moxifloxacin | + | + | + | + | + |
Nitrofurantoin | 92& | 90& | 94& | 96& | 94& |
Oxacillin/Naf | - | - | - | - | - |
Penicillin | - | - | - | - | - |
Piperacillin | 78 | 80 | 86 | + | + |
Piperacillin/tazo | 95 | 96 | 99 | 95 | 94 |
Ticarcillin/Clav | + | + | + | + | + |
Tobramycin | 93 | 94 | 97 | 98 | 94 |
TMP/SMX | 82 | 84 | 88 | 88 | 84 |
Unasyn/Aug | 11 | 0 | 0 | 0 | 0 |
Vancomycin | - | - | - | - | - |
# Tested | 153 | 261 | 213 | 258 | 267 |
Comments:
Numeric data represent local susceptibility data.
(+) = usually effective or >60% susceptible; (+/-) = clinical trials lacking or 30-60% susceptible; (-) = not effective clinically or <30% susceptible - Adapted with permission from The Sanford Guide to Antimicrobial Therapy
(*) Local (non-Sanford Guide) opinion
(S) = synergistic with penicillin/ampicillin;
(&) nitrofurantoin only useful for lower tract urinary tract infections
(+) = usually effective or >60% susceptible; (+/-) = clinical trials lacking or 30-60% susceptible; (-) = not effective clinically or <30% susceptible - Adapted with permission from The Sanford Guide to Antimicrobial Therapy
(*) Local (non-Sanford Guide) opinion
(S) = synergistic with penicillin/ampicillin;
(&) nitrofurantoin only useful for lower tract urinary tract infections